{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:09:40Z","timestamp":1784182180085,"version":"3.55.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Advanced and metastatic differentiated thyroid carcinoma (DTC), particularly radioactive iodine (RAI)-refractory disease, is characterized by spatially heterogeneous tumor biology and limited therapeutic options. Fibroblast activation protein inhibitor (FAPI)-targeted imaging may provide noninvasive imaging correlates of stromal-related tumor phenotypes; however, tracer uptake should not be interpreted as direct tissue proof of FAP expression without immunohistochemical or multi-omics validation. This exploratory study evaluated 99mTc-FAPI-YQ3 SPECT\/CT for characterizing FAPI uptake phenotypes and metabolic-stromal imaging heterogeneity in advanced DTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A quinolone-derived FAPI pharmacophore was designed using scaffold-hopping and conformational-constraint strategies and radiolabeled with 99mTc. From June 2024 to February 2025, patients with pathologically confirmed DTC and locally advanced, recurrent, nodal metastatic, or distant metastatic disease were prospectively enrolled in this single-center observational study. No formal sample-size calculation was performed because the study was designed as an exploratory first clinical imaging-radiomics analysis. All patients underwent whole-body 99mTc-FAPI-YQ3 SPECT\/CT and 18F-FDG PET\/CT within 1 week. Lesion detection, biodistribution, tumor-to-background ratio (TBR), dual-tracer concordance, and exploratory radiomics classification of FAPI uptake phenotypes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventeen patients with 103 lesions were included. The mean TBR of 99mTc-FAPI-YQ3 was 6.8 +\/- 2.3, and the mean lesion diameter was 2.69 +\/- 1.35\u00a0cm. Dual-tracer phenotypes included concordant FDG-positive\/FAPI-positive lesions (54\/103, 52.4%), FDG-positive\/FAPI-negative lesions (44\/103, 42.7%), and FDG-negative\/FAPI-positive lesions (5\/103, 4.9%); no FDG-negative\/FAPI-negative lesion was observed. Overall crude concordance was 52.4%, Cohen kappa was -0.0955 (P\u00a0=\u00a00.0477), and the positive-class Jaccard index was 0.524. 99mTc-FAPI-YQ3 showed high detection rates for thyroid-bed lesions (19\/21) and bone lesions (7\/8), moderate detection of lymph-node lesions (18\/29), and limited detection of pulmonary lesions (10\/40). In the exploratory lesion-level radiomics analysis, the logistic-regression model showed AUC values of 0.951 in the training set, 0.927 in the validation set, and 0.874 in five-fold cross-validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>99mTc-FAPI-YQ3 SPECT\/CT appears to be a feasible and accessible approach for evaluating FAPI uptake phenotypes in advanced DTC. Dual FDG-FAPI imaging provides preliminary evidence of metabolic-stromal imaging heterogeneity, but the findings should be interpreted as imaging phenotypes rather than validated tissue-based FAP expression. Further prospective studies with histopathologic, immunohistochemical, multi-omics, and patient-level validation are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1888899","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:37:44Z","timestamp":1784180264000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["99mTc-FAPI-YQ3 SPECT\/CT for characterizing FAPI uptake phenotypes and metabolic-stromal heterogeneity in advanced differentiated thyroid carcinoma: a prospective single-center imaging-radiomics study"],"prefix":"10.3389","volume":"17","author":[{"given":"Peng","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengjun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqing","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.005","article-title":"Cancer survival statistics in China 2019-2021: a multicenter, population-based study","volume":"4","author":"Zeng","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B2","article-title":"Comparison of 68Ga-FAPI-04 and 18F-FDG PET\/CT for diagnosis of metastatic lesions in patients with recurrent papillary thyroid carcinoma","volume":"26","author":"Sayiner","year":"2023","journal-title":"Hell J Nucl Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1148\/radiol.212430","article-title":"68Ga fibroblast activation protein inhibitor PET\/CT in the detection of metastatic thyroid cancer: comparison with 18F-FDG PET\/CT","volume":"304","author":"Fu","year":"2022","journal-title":"Radiology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221052","article-title":"Myocardial activity at 18F-FAPI PET\/CT and risk for sudden cardiac death in hypertrophic cardiomyopathy","volume":"306","author":"Wang","year":"2023","journal-title":"Radiology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202110-2414OC","article-title":"Comprehensive analysis of fibroblast activation protein expression in interstitial lung diseases","volume":"207","author":"Yang","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222052","article-title":"68Ga-FAPI PET\/CT for rheumatoid arthritis: a prospective study","volume":"307","author":"Luo","year":"2023","journal-title":"Radiology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749","article-title":"FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2025.07.034","article-title":"Beyond cancer: the role of radiolabeled fibroblast activation protein inhibitors (FAPI) in non-oncological molecular imaging","volume":"32","author":"Jafari","year":"2025","journal-title":"Acad Radiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265471","article-title":"Evaluation of the diagnostic accuracy of FAPI PET\/CT in oncologic studies: systematic review and meta-analysis","volume":"64","author":"Wass","year":"2023","journal-title":"J Nucl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.222785","article-title":"FAPI compared with FDG PET\/CT for diagnosis of primary and metastatic lung cancer","volume":"308","author":"Wei","year":"2023","journal-title":"Radiology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2025.02.004","article-title":"Integrating radiomics and gene expression by mapping on the image with improved DeepInsight for clear cell renal cell carcinoma","author":"Kawahara","year":"2025","journal-title":"Cancer Genet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.cancergen.2025.08.010","article-title":"Comprehensive analysis of oncogenic determinants across tumor types via multi-omics integration","author":"Ubaid","year":"2025","journal-title":"Cancer Genet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2025.07.014","article-title":"Pan-cancer methylation analysis of circulating cell-free DNA","author":"Dong","year":"2025","journal-title":"Cancer Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2025.07.010","article-title":"Unraveling prognostic biomarkers in oral squamous cell carcinoma: an approach based on explainable artificial intelligence","author":"Dogra","year":"2025","journal-title":"Cancer Genet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/imo2.19","article-title":"A glimpse into the future: Integrating artificial intelligence for precision HER2-positive breast cancer management","volume":"1","author":"Deng","year":"2024","journal-title":"iMetaOmics"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.758958","article-title":"Fibroblast-activated protein inhibitor PET\/CT: cancer diagnosis and management","volume":"11","author":"Kuyumcu","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-022-01742-8","article-title":"68Ga-DOTA-FAPI-04 PET\/CT imaging in radioiodine-refractory differentiated thyroid cancer (RR-DTC) patients","volume":"36","author":"Chen","year":"2022","journal-title":"Ann Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06067-2","article-title":"18F-FAPI-42 PET\/CT in differentiated thyroid cancer: diagnostic performance, uptake values, and comparison with 2-[18F]FDG PET\/CT","volume":"50","author":"Mu","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-06068-1","article-title":"The role of 99mTc-HFAPi SPECT\/CT in patients with Malignancies of digestive system: first clinical experience","volume":"50","author":"Jia","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005348","article-title":"Recent\u00a0clinical implications of FAPI: imaging and therapy","volume":"49","author":"Kiani","year":"2024","journal-title":"Clin Nucl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science\u00a0to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp Mol Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergen.2025.03.004","article-title":"Identification of new immune target and signaling for cancer immunotherapy","author":"Narote","year":"2025","journal-title":"Cancer Genet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202500722","article-title":"Paracrine orchestration of tumor microenvironment remodeling induced by GLO1 potentiates lymph node metastasis in breast cancer","volume":"12","author":"Xie","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-023-2491-7","article-title":"The burgeoning importance of PIWI-interacting RNAs in cancer progression","volume":"67","author":"Deng","year":"2024","journal-title":"Sci China Life Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1888899\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:37:44Z","timestamp":1784180264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1888899\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1888899"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1888899","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"article-number":"1888899"}}